| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0961203315622819 |
| P698 | PubMed publication ID | 26743322 |
| P50 | author | Amanda M Eudy | Q56363724 |
| P2093 | author name string | D Bennett | |
| D D Hill | |||
| B Haight | |||
| C E Henegar | |||
| V Kharat | |||
| P2860 | cites work | Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature | Q27477927 |
| Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors | Q28244625 | ||
| The human polyomavirus, JCV, uses serotonin receptors to infect cells | Q28294207 | ||
| PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
| Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease | Q31117183 | ||
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 | ||
| How to improve morbidity and mortality in systemic lupus erythematosus | Q33902390 | ||
| New insights into progressive multifocal leukoencephalopathy | Q34323449 | ||
| Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease | Q34538727 | ||
| Prednisone, lupus activity, and permanent organ damage | Q36761678 | ||
| Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? | Q37242800 | ||
| Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies | Q37331090 | ||
| Human polyoma viruses and disease with emphasis on clinical BK and JC. | Q37671117 | ||
| Incidence of progressive multifocal leukoencephalopathy in patients without HIV. | Q37799469 | ||
| Sorting out the risks in progressive multifocal leukoencephalopathy | Q38260098 | ||
| B cells and progressive multifocal leukoencephalopathy: search for the missing link | Q38515349 | ||
| Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). | Q39581963 | ||
| Efficacy of camptothecin in progressive multifocal leucoencephalopathy | Q42549598 | ||
| Remission of progressive multifocal leucoencephalopathy in SLE after treatment with cidofovir: a 4 year follow up. | Q43067503 | ||
| Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy | Q43264966 | ||
| JC virus leukoencephalopathy complicating Wegener’s granulomatosis | Q43638601 | ||
| Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy | Q43696859 | ||
| Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study | Q43986260 | ||
| Progressive multifocal leucoencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus | Q44049400 | ||
| Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases | Q44893878 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage | Q45099953 | ||
| Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort | Q45740730 | ||
| A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. | Q46097425 | ||
| High anti-double-stranded DNA antibodies and progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus | Q46381149 | ||
| Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. | Q47763052 | ||
| Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus | Q48302795 | ||
| Progressive multifocal leukoencephalopathy complicating systemic lupus erythematosus | Q48367819 | ||
| Mefloquine improved progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus | Q48476999 | ||
| Progressive multifocal leukoencephalopathy: clinical and radiographic features | Q48497991 | ||
| Progressive multifocal leukoencephalopathy in a patient treated with etanercept | Q48639407 | ||
| Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study | Q48828618 | ||
| Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency | Q48859415 | ||
| Progressive multifocal leukoencephalopathy - the importance of early diagnosis illustrated in four cases | Q48882862 | ||
| Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. | Q54656453 | ||
| P433 | issue | 6 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| progressive multifocal leukoencephalopathy | Q704930 | ||
| P304 | page(s) | 617-626 | |
| P577 | publication date | 2016-01-06 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review | |
| P478 | volume | 25 |
| Q59349114 | A Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic Lupus Erythematosus Is an Early Sign of Progressive Multifocal Leukoencephalopathy: A Clinicopathological Study |
| Q55429200 | A case of developing progressive multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic lupus erythematosus. |
| Q104559093 | COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease |
| Q40543791 | Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database |
| Q91635987 | Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy |
| Q33736193 | High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study |
| Q49906338 | Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies |
| Q36271212 | Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE). |
| Q38816869 | Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future |
| Q47837398 | Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. |
| Q88551231 | Pediatric Neuromyelitis Optica Spectrum Disorders |
| Q30245002 | Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. |
| Q39034482 | Reducing persistent polyomavirus infection increases functionality of virus-specific memory CD8 T cells |
| Q92281461 | Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? |
| Q91640209 | Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus |
| Q38833876 | Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus |
| Q39231543 | The role of infections in neuropsychiatric lupus |
| Q38829637 | The safety of pharmacological treatment options for lupus nephritis |
Search more.